Alnylam is the world’s leading RNA interference (RNAi) company.
Founded in 2002, Alnylam was built upon a bold vision of turning scientific possibility into reality by harnessing the power of RNAi for human health as an innovative new class of medicines.
We are a growing biopharmaceutical company with two approved medicines and a robust pipeline of investigational medicines focused in four strategic therapeutic areas : genetic medicines, cardio-metabolic diseases, infectious diseases, central nervous system (CNS) and ocular diseases, including several in late-stage development.
Headquartered in Cambridge, Mass., Alnylam employs over 1,400 people in 19 countries and is rapidly growing globally, with additional offices in Norton, Mass.
Maidenhead, Zug, Switzerland, Amsterdam, Netherlands, and Tokyo, Japan. Alnylam is proud to have been recognized as one of The Boston Globe’s Top Places to Work five years in a row (2015-2019), a Great Place to Work in the and Switzerland in 2020 and Science Magazine’s #1 Top Employer in 2019.
Please visit for more information.
As capabilities and IT system deployment increase in ex-US countries, coordinating efforts and requirements in those countries with US teams is increasingly more complex.
The Capabilities Portfolio Manager will manage efforts across CEMEA, LATAM and ASIA, orchestrating IT and the regional business leadership teams towards the successful delivery of the IT Portfolio and Capabilities Roadmap in these regions.
This role can be based in Maidenhead, UK or Amsterdam, Netherlands.
Summary of Key Responsibilities